CA3208780A1 - Procede de purification de macro-agregats de serumalbumine humaine radiomarques - Google Patents

Procede de purification de macro-agregats de serumalbumine humaine radiomarques Download PDF

Info

Publication number
CA3208780A1
CA3208780A1 CA3208780A CA3208780A CA3208780A1 CA 3208780 A1 CA3208780 A1 CA 3208780A1 CA 3208780 A CA3208780 A CA 3208780A CA 3208780 A CA3208780 A CA 3208780A CA 3208780 A1 CA3208780 A1 CA 3208780A1
Authority
CA
Canada
Prior art keywords
maa
syringe filter
radiolabeled
pendes
99mtc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3208780A
Other languages
English (en)
Inventor
Thomas VERGOTE
Julien MASSET
Corentin WARNIER
Jean-Luc Morelle
Charles VRIAMONT
Frederique Blanc-Beguin
Pierre-Yves LEROUX
Peter EU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trasis SA
Original Assignee
Trasis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trasis SA filed Critical Trasis SA
Publication of CA3208780A1 publication Critical patent/CA3208780A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne un procédé pour la purification de macro- agrégats de sérumalbumine humaine (MAA) radio-marquée dans une solution injectable à un patient en utilisant un filtre de seringue, caractérisé en ce que le filtre de seringue utilisé a la caractéristique de piéger et de libérer le MAA radio-marqué tandis que les impuretés de la solution totale ne sont pas retenues.
CA3208780A 2021-01-28 2022-01-24 Procede de purification de macro-agregats de serumalbumine humaine radiomarques Pending CA3208780A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE20215067A BE1027699B1 (fr) 2021-01-28 2021-01-28 Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
BE2021/5067 2021-01-28
PCT/EP2022/051434 WO2022161897A1 (fr) 2021-01-28 2022-01-24 Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués

Publications (1)

Publication Number Publication Date
CA3208780A1 true CA3208780A1 (fr) 2022-08-04

Family

ID=75302187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3208780A Pending CA3208780A1 (fr) 2021-01-28 2022-01-24 Procede de purification de macro-agregats de serumalbumine humaine radiomarques

Country Status (10)

Country Link
US (1) US20240076248A1 (fr)
EP (1) EP4284771A1 (fr)
JP (1) JP7862407B2 (fr)
KR (1) KR20230137371A (fr)
CN (1) CN116806212B (fr)
AU (1) AU2022212395A1 (fr)
BE (1) BE1027699B1 (fr)
CA (1) CA3208780A1 (fr)
IL (1) IL304662B2 (fr)
WO (1) WO2022161897A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115104159A (zh) * 2020-02-21 2022-09-23 布拉科诊断公司 放射性同位素发生器早期突破检测
WO2025099636A1 (fr) * 2023-11-08 2025-05-15 Jubilant Draximage Inc Conjugués d'albumine et compositions radiopharmaceutiques associées

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8105464A (nl) * 1981-12-04 1983-07-01 Philips Nv Werkwijze voor het vervaardigen van een lagedrukkwikdampontladingslamp.
CN85109606A (zh) * 1985-12-05 1987-06-17 上海市肿瘤研究所 逆向斑点分子杂交技术
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6730286B2 (en) 2001-02-28 2004-05-04 Bracco Diagnostics, Inc. Manufacturing process to control particle size
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
JP2014025794A (ja) 2012-07-26 2014-02-06 Koyo:Kk 放射能除染装置
JP2019152525A (ja) 2018-03-02 2019-09-12 国立研究開発法人産業技術総合研究所 海水中の希薄な放射性セシウムのモニタリング方法
CN111358965A (zh) * 2020-01-22 2020-07-03 哈尔滨医科大学 68Ga标记NOTA修饰的EGFR分子成像探针及制备与应用
CN112067515B (zh) * 2020-09-03 2023-04-25 南昌大学 一种均相检测大分子抗原的动态光散射免疫方法

Also Published As

Publication number Publication date
BE1027699A1 (fr) 2021-05-18
IL304662B1 (en) 2025-04-01
JP2024504453A (ja) 2024-01-31
CN116806212B (zh) 2025-07-11
CN116806212A (zh) 2023-09-26
IL304662A (en) 2023-09-01
JP7862407B2 (ja) 2026-05-19
AU2022212395A9 (en) 2025-01-30
WO2022161897A1 (fr) 2022-08-04
IL304662B2 (en) 2025-08-01
US20240076248A1 (en) 2024-03-07
KR20230137371A (ko) 2023-10-04
AU2022212395A1 (en) 2023-07-20
EP4284771A1 (fr) 2023-12-06
BE1027699B1 (fr) 2022-04-01

Similar Documents

Publication Publication Date Title
Westrøm et al. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution
Blower et al. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies
Guhlke et al. Simple new method for effective concentration of 188Re solutions from alumina-based 188W—188Re Generator
Saha Characteristics of specific radiopharmaceuticals
Tworowska et al. Radiosynthesis of clinical doses of 68Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68Ge/68Ga generators
CA3160031A1 (fr) Fabrication de 212pb hautement purifie
KR101948404B1 (ko) 양전자 방출 단층촬영에 사용하기 위한 43sc 방사성핵종 및 그의 방사성제약의 제조
CA2816070A1 (fr) Procede et trousse de preparation d'un produit radiopharmaceutique
US20240076248A1 (en) Method for purification of radiolabeled macroaggregated human serum albumin
McCarthy et al. Nuclear medicine and positron emission tomography: an overview
Krasikova et al. Yttrium-90: Application in Nuclear Medicine and Production in Radionuclide Generators
AU2013261858A1 (en) Kit and method for producing a radiopharmaceutical
Knapp Jr et al. Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands
Hassanpour et al. Effect of Eluting the 99Mo/99 m Tc Generator More than Once in 24 h on the Efficiency of the 99 m Tc-MIBI Complex
KR102873341B1 (ko) 다중 제너레이터를 이용한 방사성의약품 제조방법
AU2013261867A1 (en) Set and method for the production of a radiopharmaceutical
Munir et al. Development and pre-clinical evaluation of new 99Mo/99mTc generator prototype based on zirconium-based material (ZBM)
RU2807899C1 (ru) Способ автоматизированного синтеза радиофармпрепаратов на основе полимерных микрочастиц с использованием устройства для его осуществления
De La Fuente et al. Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes
Zhernosekov Radiochemical aspects of production and processing of radiometals for preparation of metalloradiopharmaceuticals
Moschini et al. A Cyclotron Isotope Production Center For Biomedical Research
AU2013261855A1 (en) Set and method for the production of a radiopharmaceutical
Leyva Montaña et al. Yttrium-90–Current Status, Expected Availability and Applications of a High Beta Energy Emitter
WO2010000714A2 (fr) Kit de radio-immunoconjugué
Notation Radioactivity, Radionuclides, and Radiopharmaceuticals

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260127

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128